Browse Tag

breast cancer

March 1, 2021March 1, 2021

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2-) negative, advanced breast cancer with a PIK3CA mutation

October 15, 2017October 15, 2017

How are Cancers Found and Diagnosed?

Cancer is the plague of the modern age. It is very prevalent,

Pharmaceutical News

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

March 1, 2021March 1, 2021

Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of

Pharma Interest

How are Cancers Found and Diagnosed?

October 15, 2017October 15, 2017

Cancer is the plague of the modern age. It is very prevalent, to the point where it is estimated that

<img src="http://www.pharmamirror.com/wp-content/uploads/2018/01/Pharma-Mirror.png" alt="Mobile Logo" width="330" height="77">

breast cancer

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

How are Cancers Found and Diagnosed?

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

How are Cancers Found and Diagnosed?